CurrentOptumPolicy BH803 NYTMS122025

New York Medicaid and Essential Plan: Transcranial Magnetic Stimulation (TMS) - Medicaid, Child Health Plus and Essential Plan

State-specific supplemental clinical criteria governing coverage and medical necessity determinations for TMS for New York Medicaid, Child Health Plus, and Essential Plan members; applies to providers requesting authorization for TMS services under those programs.

Policy Summary

PayerOptum

PolicyTranscranial Magnetic Stimulation (TMS) for Treatment-Resistant Major Depressive Disorder — NY Medicaid, Child Health Plus, Essential Plan

Policy CodePolicy BH803 NYTMS122025

Change TypeMaterial updates — added coverage scope, definitions, and provider requirements

Effective DateNov 1, 2025

Next Review DateNov 1, 2026

Key ActionObtain prior authorization showing member is ≥18, meets the definition of treatment-resistant MDD (two adequate antidepressant trials), and that a qualified psychiatrist will perform TMS.

SourceLink

POLICY UPDATE CHANGES

Transcranial Magnetic Stimulation is available for NYS Medicaid members 18 years and older diagnosed with treatment-resistant MDD, effective November 1, 2025 for Medicaid and Child Health Plus and November 1, 2026 for Essential Plans.

Treatment resistance is defined as two trials of a therapeutic dose of two different antidepressants for a sufficient duration without a clinically meaningful response.

TMS must be performed by a qualified psychiatrist with specialized training and certification.

Obsessive-compulsive disorder (OCD) is not an indication for NYS Medicaid reimbursement for TMS.

18+Minimum age

2 trialsPrior treatment trials

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage and Medical Necessity Criteria

inv-01: Coverage Criteria for TMS

Covered when ALL of the following are met:

Eligibility and diagnosis: Member is a New York State Medicaid (FFS or MMC), Child Health Plus enrollee, or Essential Plan member (EP effective 11/1/2026) and is age 18 or older with a diagnosis of treatment-resistant major depressive disorder.>= 18 years

Effective dates: NYS Medicaid/CHP effective 11/1/2025; EP effective 11/1/2026.

Treatment resistance: Documentation of two trials of a therapeutic dose of two different antidepressants for a sufficient duration without a clinically meaningful response.2 adequate antidepressant trials

Operational definition of treatment resistance used for authorization determinations.

Clinical evaluation: Provider confirms diagnosis and rules out other etiologies of depressive symptoms that could interfere with medication effectiveness.

Required prior to initiation of TMS.

Treatment setting and provider: TMS must be performed by a qualified psychiatrist with specialized training and certification.

Provider qualification required for service provision.

Exclusions: TMS is not indicated for acute suicidality, psychotic depression, primary neurological disorders, or obsessive-compulsive disorder (OCD) (OCD not an indication for NYS Medicaid reimbursement).

Requests for these indications are not covered under this policy.

Coverage limitations and exclusions: Transcranial Magnetic Stimulation (TMS) is not indicated for acute suicidality, psychotic depression, or primary neurological disorders. Additionally, obsessive-compulsive disorder (OCD) is explicitly not an indication for New York State Medicaid reimbursement for TMS under this policy.

TMS is not first-line therapy for depression and, under this policy, the use of TMS as the initial treatment for depressive disorders is not medically necessary. Prior to authorization, members must meet the policy’s defined criteria for treatment-resistant major depressive disorder.

Procedure and Diagnosis Codes; Member Eligibility

Applicable CPT CodesCPT

90867	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; initial, including cortical mapping, motor threshold determination, delivery and management.
90868	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent delivery and management, per session.
90869	Therapeutic repetitive transcranial magnetic stimulation (TMS) treatment; subsequent motor threshold re-determination with delivery and management.

Example ICD-10 Diagnosis CodesICD-10

F32.2	Major depressive disorder, single episode, severe without psychotic features.
F33.2	Major depressive disorder, recurrent severe without psychotic features.

Minimum age for TMS coverage

Minimum member ageMember must be 18 years of age or older (≥ 18)

Effective date (NY coverage scope)Effective November 1, 2025 for NYS Medicaid and Child Health Plus; Essential Plans effective November 1, 2026

ApplicabilityApplies to NYS Medicaid fee-for-service, Medicaid Managed Care, and Child Health Plus (and Essential Plans per effective date)

Authorization, Documentation, and Denial Triggers

Prior Authorization

Prior Authorization Required

Prior authorization is required before initiating TMS. Requests must document the member is 18 years of age or older and meets the policy definition of treatment‑resistant major depressive disorder (see coverage criteria).

Applies to NYS Medicaid FFS, MMC, and Child Health Plus (EP plans effective 11/01/2026)

Step Therapy

Prior Treatment (Step Therapy)

TMS is not a first‑line therapy for depression. Prior to authorization, providers must document at least two adequate trials of therapeutic doses of two different antidepressant medications without achieving a clinically meaningful response. Provider documentation should include medication names, doses, start/stop dates, duration, and reason for discontinuation (lack of efficacy or intolerance).

Requirement: ≥2 trials of different antidepressants at therapeutic dose and adequate duration
TMS contraindicated as first‑line treatment or for acute suicidality, psychotic depression, or primary neurological disorders

Clinical Background

Transcranial Magnetic Stimulation (TMS) is a non-invasive brain stimulation therapy used to improve symptoms of major depressive disorder when conventional treatments have failed. Under this policy TMS is indicated for adults with treatment-resistant major depressive disorder who meet the specified prior-treatment, diagnostic, and provider qualifications.

Operational Definitions

Treatment-resistant major depressive disorder (MDD) — operational definition

Operational definitionTreatment-resistant MDD is defined as failure to achieve a clinically meaningful response after two trials of a therapeutic dose of two different antidepressants for a sufficient duration.

Required documentation of trialsProvide documentation of the two antidepressant trials including agent names, therapeutic doses, and durations on authorization requests.

Clinical evaluation requirementProvider must confirm diagnosis and rule out other etiologies of depressive symptoms that could interfere with medication effectiveness before initiating TMS.

Context of useTMS is indicated for treatment-resistant MDD in adults when conventional treatments have failed; it is not first-line therapy.

TMS Delivery and Modalities

inv-13: TMS — modality-specific notes

TMS modality description: Transcranial Magnetic Stimulation is a non-invasive brain stimulation therapy used to improve symptoms of major depressive disorder when conventional treatments have failed.

Performed by trained, certified psychiatrists for treatment-resistant MDD in adults as specified in coverage criteria.